These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22591754)

  • 21. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
    Ben-Hamadi R; Duh MS; Aggarwal J; Henckler A; McKenzie RS; Tak Piech C
    Curr Med Res Opin; 2005 Oct; 21(10):1677-82. PubMed ID: 16238908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
    Nurko S; Spirko R; Law A; Dennis VW
    Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
    Patton J; Reeves T; Wallace J
    Oncologist; 2004; 9(4):451-8. PubMed ID: 15266098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
    Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals.
    Spaepen E; Demarteau N; Van Belle S; Annemans L
    Oncologist; 2008 May; 13(5):596-607. PubMed ID: 18515745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose requirements among hemodialysis patients treated with darbepoetin-alpha or epoetin-beta.
    Prata MM; Dos Santos JP; Hegbrant J; Schmid CH; Pereira BJ; Wald R
    Nephron Clin Pract; 2007; 107(2):c50-5. PubMed ID: 17713351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
    Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.
    Wish JB; Coyne DW
    Mayo Clin Proc; 2007 Nov; 82(11):1371-80. PubMed ID: 17976358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.
    Pashos CL; Larholt K; Fraser KA; McKenzie RS; Senbetta M; Piech CT
    Support Care Cancer; 2012 Jan; 20(1):159-65. PubMed ID: 21359879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management.
    Vansteenkiste JF
    Cancer Treat Rev; 2006; 32 Suppl 2():S11-5. PubMed ID: 16725268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa.
    Hymes J; Bickimer T; Jackson JH; Bookhart BK; Mody SH; Tak Piech C
    Curr Med Res Opin; 2007 Aug; 23(8):1931-7. PubMed ID: 17624232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of erythropoiesis-stimulating agent prescribing at an Asian cancer center, after release of safety advisories.
    Chan Q; Chan A
    J Oncol Pharm Pract; 2011 Dec; 17(4):350-9. PubMed ID: 20659968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy-induced anemia: the story of darbepoetin alfa.
    Vansteenkiste J; Wauters I; Elliott S; Glaspy J; Hedenus M
    Curr Med Res Opin; 2013 Apr; 29(4):325-37. PubMed ID: 23323876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
    Lafeuille MH; Bailey RA; Vekeman F; Scott McKenzie R; Lefebvre P
    J Med Econ; 2012; 15(2):352-60. PubMed ID: 22168787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
    Voils SA; Harpe SH; Brophy GM
    Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective.
    Rubin RJ; Glaspy JA; Adams JL; Mafilios MS; Wang SM; Viswanathan HN; Kallich JD
    J Med Econ; 2008; 11(2):199-213. PubMed ID: 19450080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia.
    Noxon V; Knopf KB; Norris LB; Chen B; Yang YT; Qureshi ZP; Hrushesky W; Lebby AA; Schooley B; Hikmet N; Dickson M; Thamer M; Cotter D; Yarnold PR; Bennett CL
    J Oncol Pract; 2017 Jun; 13(6):e562-e573. PubMed ID: 28504901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
    Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase III clinical trials with darbepoetin: implications for clinicians.
    Glaspy J
    Best Pract Res Clin Haematol; 2005; 18(3):407-16. PubMed ID: 15792914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.